Leap Therapeutics (LPTX) shares were down nearly 13% in recent trading Wednesday after Baird and HC Wainwright downgraded the stock to neutral.
Baird also trimmed its price target to $1.25 from $9. The stock was previously rated outperform at Baird and buy at HC Wainwright.
Almost 3 million shares traded so far, compared with a daily average of about 612,000.
Price: 0.57, Change: -0.08, Percent Change: -12.92
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.